Selling, General, and Administrative Costs: Bio-Techne Corporation vs Ascendis Pharma A/S

A Comparative Analysis of SG&A Expenses in the Biotech Sector

In the ever-evolving biotech industry, understanding financial trends is crucial for investors and stakeholders. This analysis focuses on the Selling, General, and Administrative (SG&A) expenses of two prominent companies: Bio-Techne Corporation and Ascendis Pharma A/S, from 2014 to 2023.

Bio-Techne Corporation has consistently demonstrated robust growth, with SG&A expenses increasing by over 500% from 2014 to 2023. This reflects their strategic investments in expanding operations and market reach. In contrast, Ascendis Pharma A/S, while showing a significant rise in SG&A expenses, experienced a more volatile trajectory, with a notable surge of over 400% during the same period.

The data highlights Bio-Techne's steady financial management and Ascendis Pharma's aggressive expansion strategy. As the biotech sector continues to grow, these insights provide a window into the financial health and strategic priorities of these industry leaders.

Key Insights

• Bio-Techne's SG&A expenses grew steadily, indicating stable expansion.
• Ascendis Pharma's expenses showed volatility, reflecting aggressive growth strategies.
• Missing data for 2024 suggests ongoing developments in Bio-Techne's financial strategy.